AUS
NZ
UK
CA
USA
IND
Highlights
- FT819 delivers sustained clinical improvements in treatment-refractory Systemic Lupus Erythematosus (SLE) patients.
- Favorable safety profile with no dose-limiting toxicities or neurotoxicity observed.
- Company in discussions with FDA under RMAT designation for a pivotal study in 2026.
Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical firm advancing induced pluripotent stem cell-derived off-the-shelf cell therapies, presented updated clinical findings from its Phase 1 trial of FT819 during the American College of Rheumatology Convergence 2025 held in Chicago.
The study included 10 patients with treatment-resistant, moderate-to-severe Systemic Lupus Erythematosus who received a single infusion of FT819, either with reduced-intensity or no conditioning chemotherapy. Based on September 25, 2025, data cut-off results demonstrated immune system remodeling and durable clinical responses.
Key Clinical Findings
Patients treated with FT819 under less-intensive or conditioning-free regimens exhibited significant clinical improvements:
- All participants who passed the three-month follow-up (n=5) showed decreases in SLE Disease Activity Index and Physician’s Global Assessment scores.
- Two patients with lupus nephritis (LN) achieved complete renal response by six months, with one maintaining steroid-free remission at the 15-month follow-up.
- Patients treated without conditioning chemotherapy demonstrated meaningful disease reduction, indicating feasibility for outpatient administration.
No dose-limiting toxicities, immune effector cell-associated neurotoxicity syndrome (ICANS), or graft-versus-host disease events were reported. Three patients experienced low-grade cytokine release syndrome, all of which were manageable.
Translational Insights
Results showed rapid and sustained CD19+ B cell depletion, followed by the reappearance of naïve B cells, indicating immune rebalancing correlated with reduced disease activity. This immune remodeling was seen in both conditioning and non-conditioning regimens, supporting FT819’s ability to reset the B-cell compartment in autoimmune disease contexts.
Study Design and Next Steps
The multi-center Phase 1 study is structured around two treatment approaches:
- Regimen A: Reduced intensity chemotherapy (cyclophosphamide or bendamustine).
- Regimen B: Conditioning free therapy added to ongoing maintenance treatment.
Building on the early results, Fate Therapeutics is working with the U.S. Food and Drug Administration under its Regenerative Medicine Advanced Therapy designation to finalize a registrational study design, with the goal of launching a pivotal trial in 2026.
Program Expansion
The company has also opened dose-expansion cohorts for FT819 in additional autoimmune diseases, including anti-neutrophilic cytoplasmic antibody-associated vasculitis, idiopathic inflammatory myositis, and systemic sclerosis. Fate Therapeutics reports having approximately 600 cryopreserved FT819 drug product bags available to support these ongoing and upcoming studies.
Management Commentary
“This promising initial clinical data demonstrates that FT819 can deliver transformative outcomes in patients with moderate-to-severe SLE, particularly with reduced or no conditioning chemotherapy,” said Bob Valamehr, Ph.D., M.B.A., President and Chief Executive Officer of Fate Therapeutics. “We continue to engage with the FDA on a registrational study design with the goal of initiating a pivotal study next year.”
